Literature DB >> 25772063

Organ-protective effects on the liver and kidney by minocycline in small piglets undergoing cardiopulonary bypass.

Stefan Dhein1, Maria Grassl, Maria Gerdom, Marcel Vollroth, Farhad Bakhtiary, Sandy von Salisch, Klaus Krämer, Axel Sobiraj, Martin Kostelka, Friedrich-Wilhelm Mohr, Aida Salameh.   

Abstract

Cardiopulmonary bypass (CPB) often is required for the operative correction of congenital heart defects in small infants. Unfortunately, CPB is associated with injury of inner organs such as the brain, kidney, lung, and liver. Renal failure and increase in liver enzymes are typical side effects observed after CPB. Here, we investigate whether organ protection of the kidney and liver can be achieved with the application of minocycline, which is known-besides its anti-infective effects-to act as a poly-ADP-ribose-polymerase inhibitor. Twenty-nine 4-week-old Angler Sattelschwein-piglets (8-15 kg) were divided into four groups: control group (n = 8), CPB group (n = 9), minocycline-control group (n = 6), and the minocycline-CPB group (n = 6). CPB groups were thoracotomized and underwent CPB for 120 min (cross-clamp, 90 min; reperfusion, 30 min) followed by a 90-min recovery time. The control groups also were thoracotomized but not connected to CPB. The minocycline group received 4 mg/kg minocycline before and 2 mg/kg after CPB. In the kidneys, CPB histologically resulted in widening of Bowman's capsule, and-mainly in tubules-formation of poly-ADP-ribose, nitrosylation of tyrosine-residues, nuclear translocation of hypoxia-induced factor HIF-1α, and of apoptosis-inducing factor (AIF). In addition, we found significantly less ATP in the kidney and significantly increased plasma urea and creatinine. Similar but gradually attenuated changes were found in the liver together with significantly elevated de-Ritis coefficient. These changes in the kidney and liver were significantly diminished by minocycline (except AIF in the liver which was similar in all groups). In conclusion, CPB causes damage in the kidney and-to a lower degree-in the liver, which can be attenuated by minocycline.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772063     DOI: 10.1007/s00210-015-1115-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  40 in total

1.  Acute renal failure and mortality after open-heart surgery in infants.

Authors:  Esra Baskin; Arda Saygili; Koray Harmanci; Pinar Isik Agras; F Nurhan Ozdemir; Sükrü Mercan; Kürsad Tokel; Umit Saatci
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

Review 2.  Pathophysiology of contrast-induced nephropathy.

Authors:  James Tumlin; Fulvio Stacul; Andy Adam; Christoph R Becker; Charles Davidson; Norbert Lameire; Peter A McCullough
Journal:  Am J Cardiol       Date:  2006-02-17       Impact factor: 2.778

3.  Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest.

Authors:  Terézia B Andrási; Anna Blázovics; Gábor Szabó; Christian F Vahl; Siegfried Hagl
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-01-28       Impact factor: 4.733

4.  Splanchnic organ injury during coronary surgery with or without cardiopulmonary bypass: a randomized, controlled trial.

Authors:  Raimondo Ascione; Sudath Talpahewa; Chanaka Rajakaruna; Barnaby C Reeves; A Timothy Lovell; Alan Cohen; Gianni D Angelini
Journal:  Ann Thorac Surg       Date:  2006-01       Impact factor: 4.330

5.  The effects of tetracyclines and erythromycin on complement activation in vitro.

Authors:  E Ingham
Journal:  Acta Derm Venereol       Date:  1990       Impact factor: 4.437

6.  New model of renal warm ischaemia-reperfusion injury for comparative functional, morphological and pathophysiological studies.

Authors:  S C Weight; P N Furness; M L Nicholson
Journal:  Br J Surg       Date:  1998-12       Impact factor: 6.939

7.  INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.

Authors:  Gábor Szabó; Pál Soós; Susanne Mandera; Ulrike Heger; Christa Flechtenmacher; Susanne Bährle; Leila Seres; Attila Cziráki; Andre Gries; Zsuszanna Zsengellér; Christian F Vahl; Siegfried Hagl; Csaba Szabó
Journal:  Shock       Date:  2004-05       Impact factor: 3.454

8.  Development of an HPLC method for determination of metabolic compounds in myocardial tissue.

Authors:  M G Volonté; G Yuln; P Quiroga; A E Consolini
Journal:  J Pharm Biomed Anal       Date:  2004-05-28       Impact factor: 3.935

9.  Ischemic and inflammatory lung impairment by extracorporeal circulation: effect of PARP-inhibition by INO1001.

Authors:  S Dhein; N Krause; C Ullmann; A Flister; S Lehmann; P Muth; T Walther; M Kostelka; F W Mohr
Journal:  Pharmacol Res       Date:  2008-09-23       Impact factor: 7.658

10.  The decreasing incidence of late posttraumatic acute respiratory distress syndrome: the potential role of lung protective ventilation and conservative transfusion practice.

Authors:  David Plurad; Mathew Martin; Donald Green; Ali Salim; Kenji Inaba; Howard Belzberg; Demetrios Demetriades; Peter Rhee
Journal:  J Trauma       Date:  2007-07
View more
  8 in total

Review 1.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

2.  Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress.

Authors:  Chongshan Dai; Giuseppe D Ciccotosto; Roberto Cappai; Yang Wang; Shusheng Tang; Xilong Xiao; Tony Velkov
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

3.  Effects of SDF-1/CXCR4 on Acute Lung Injury Induced by Cardiopulmonary Bypass.

Authors:  Hai Shi; Rujian Lu; Shuo Wang; Honglin Chen; Fei Wang; Kun Liu
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

4.  Relaxin does not prevent development of hypoxia-induced pulmonary edema in rats.

Authors:  Ute Kowalleck; Mohamed A Abdalla Ahmed; Julia Koedel; Katrin Schierle; Aida Salameh; Beate Rassler
Journal:  Pflugers Arch       Date:  2022-07-02       Impact factor: 4.458

Review 5.  Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Front Pharmacol       Date:  2015-12-22       Impact factor: 5.810

6.  Resolvin D1 mitigates energy metabolism disorder after ischemia-reperfusion of the rat lung.

Authors:  Qifeng Zhao; Ji Wu; Qingwang Hua; Zhiyong Lin; Leping Ye; Weixi Zhang; Guowei Wu; Jie Du; Jie Xia; Maoping Chu; Xingti Hu
Journal:  J Transl Med       Date:  2016-03-24       Impact factor: 5.531

7.  Blood cytokine expression correlates with early multi-organ damage in a mouse model of moderate hypothermia with circulatory arrest using cardiopulmonary bypass.

Authors:  Ruslan Natanov; Faikah Gueler; Christine S Falk; Christian Kühn; Ulrich Maus; Erin C Boyle; Thierry Siemeni; Ann-Katrin Knoefel; Serghei Cebotari; Axel Haverich; Nodir Madrahimov
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

8.  Anti-oxidative or anti-inflammatory additives reduce ischemia/reperfusions injury in an animal model of cardiopulmonary bypass.

Authors:  Aida Salameh; Stefan Dhein; Marie Mewes; Sophie Sigusch; Philipp Kiefer; Marcel Vollroth; Johannes Seeger; Ingo Dähnert
Journal:  Saudi J Biol Sci       Date:  2019-04-05       Impact factor: 4.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.